Inzucchi, S. E., Fitchett, D., Jurišić Eržen, D., Woo, V., Hantel, S., Janista, C. ... Zinman, B. (2020). Are the cardiovascular and kidney benefits of
empagliflozin influenced by baseline glucose‐
lowering therapy?. Diabetes, Obesity and Metabolism, 22. (4), 631-639. doi: 10.1111/dom.13938
Inzucchi, Silvio E., et al. "Are the cardiovascular and kidney benefits of
empagliflozin influenced by baseline glucose‐
lowering therapy?." Diabetes, Obesity and Metabolism, vol. 22, br. 4, 2020, str. 631-639. https://doi.org/10.1111/dom.13938
Inzucchi, Silvio E., David Fitchett, Dubravka Jurišić Eržen, Vincent Woo, Stefan Hantel, Christina Janista, Stefan Kaspers, Jyothis T. George i Bernard... Zinman. "Are the cardiovascular and kidney benefits of
empagliflozin influenced by baseline glucose‐
lowering therapy?." Diabetes, Obesity and Metabolism 22, br. 4 (2020): 631-639. https://doi.org/10.1111/dom.13938
Inzucchi, S. E., et al. (2020) 'Are the cardiovascular and kidney benefits of
empagliflozin influenced by baseline glucose‐
lowering therapy?', Diabetes, Obesity and Metabolism, 22(4), str. 631-639. doi: 10.1111/dom.13938
Inzucchi SE, Fitchett D, Jurišić Eržen D, Woo V, Hantel S, Janista C, i sur.. Are the cardiovascular and kidney benefits of
empagliflozin influenced by baseline glucose‐
lowering therapy?. Diabetes, Obesity and Metabolism [Internet]. 2020. [pristupljeno 25.12.2024.];22(4):631-639. doi: 10.1111/dom.13938
S. E. Inzucchi, et al., "Are the cardiovascular and kidney benefits of
empagliflozin influenced by baseline glucose‐
lowering therapy?", Diabetes, Obesity and Metabolism, vol. 22, br. 4, str. 631-639, 2020. [Online]. Dostupno na: https://urn.nsk.hr/urn:nbn:hr:184:877245. [Citirano: 25.12.2024.]